DSIP on Juno

What it does

Delta Sleep-Inducing Peptide (DSIP) is a 9-amino-acid peptide first isolated in 1977 by the Schoenenberger / Monnier group from rabbit cerebral venous blood collected during electrically induced delta-wave sleep. It generated substantial interest in the 1980s, with a series of small clinical studies in chronic insomnia, narcolepsy, and opioid/alcohol withdrawal — most of them in European labs, most with small sample sizes, and most without independent replication. Interest in DSIP largely faded after the 1990s; the modern peptide-community revival has not been accompanied by new high-quality clinical work. The endogenous receptor for DSIP has never been identified, which is itself a striking gap for a peptide named for a specific physiological function.

Used for

Dose

Starting: 100 mcg · once daily, evening
Common: 300 mcg · once daily, evening
Upper: 500 mcg · once daily, evening
When: BedtimeDelta Sleep Inducing Peptide — administered 30 minutes before lights-out in the original sleep studies. Bedtime is the only timing this peptide makes sense at.
Site: subcutaneous (community / 1980s clinical extrapolation)

Need exact volumes? Open the peptide calculator →

⚠ Caution

Pregnancy and breastfeeding (no human safety data)
Concurrent CNS depressants (additive sedation risk has not been characterized in modern trials)
Active addiction in unmonitored settings (the withdrawal-modulation claim is not robust enough to support unsupervised use)
Known hypersensitivity to peptide formulations

Often stacked with

Epithalon — DSIP targets delta-wave sleep initiation via central neuromodulation; Epithalon purportedly restores pineal melatonin rhythms — complementary sleep-phase mechanisms, different courses require separate administration.

Your stack

Track this peptide in your protocol — dose, schedule, vials on hand, refill projection. Stays in your browser; no account needed.

Add to my stack

Use this peptide

Featured in protocols

Sleep Optimization — Phase 2 — Add sleep-architecture layer (DSIP)

Co-injection & overlap

Inject separately (do not co-mix): Epithalon

Reconstitution & storage

Lyophilized powder reconstituted with bacteriostatic water. A 5 mg vial in 2.5 mL BAC water = 2 mg/mL, making a 100 mcg dose = 5 units on a U-100 syringe. Intranasal preparations follow Juno's nasal-spray prep guide.

Storage. Lyophilized: refrigerate. Reconstituted: refrigerate 2–8 °C, use within 30 days.

Open the peptide calculator →

Reference

How it works

Despite the name, DSIP's mechanism of action is not well characterized. No specific receptor has been identified. Proposed mechanisms include modulation of the limbic-hypothalamic axis, possible interaction with opioid systems (relevant to its withdrawal-modulation claims), and pleiotropic neuromodulatory effects. The peptide is reported to cross the blood-brain barrier despite its size, but quantitative CNS pharmacokinetics in humans are essentially absent.

EvidenceTier 3 — Animal / in vitro

Tiers are per indication. The same molecule can be Tier 1 for one use and Tier 4 for another — the tier reflects published literature, not community framing.

Chronic insomnia / sleep quality

Tier 3medium confidence

Several small open-label and pseudo-controlled studies in the 1980s reported subjective sleep improvements in chronic insomnia. Sample sizes were small, methodology was pre-modern, and replication has been minimal. Per Skill Rule 5 (old, unreplicated studies are weaker than they look).

Schneider-Helmert D et al. 1986

Narcolepsy / disorders of arousal

Tier 3low confidence

A few small 1980s reports in narcolepsy and disorders of arousal. Not pursued in the modern sleep-medicine era; has been completely supplanted by orexin antagonists, sodium oxybate, and newer agents.

No primary citations are anchored to this indication — the tier reflects the absence of usable literature, not a missing reference.

Opioid / alcohol withdrawal modulation

Tier 3low confidence

Small 1980s European reports of reduced withdrawal severity in opioid-dependent and alcohol-dependent patients. Mechanism plausible (opioid-system interaction). No modern replication; addiction medicine has moved on to better-supported pharmacotherapies.

Dick P et al. 1984

General 'recovery' / community sleep-stack use

Tier 4high confidence

Modern community use (often combined with peptide stacks for 'sleep optimization') is unsupported by any controlled trial in healthy adults. The 1980s clinical work was in patient populations with diagnosed sleep or addiction disorders, not healthy users seeking optimization.